Female enrollment in PMA trials will be addressed in FDA guidance.
This article was originally published in The Gray Sheet
Executive Summary
ENROLLMENT OF WOMEN IN PMA STUDIES WILL BE ADDRESSED IN FDA GUIDANCE under development within the device center's Office of Device Evaluation, according to agency staffers. The guidance is being developed in response to a March 1 report from the device center's internal working group on women's health issues that concluded that the agency should "develop clinical protocol guidance that requires appropriate enrollment of both genders" in trials to support premarket approval applications.
You may also be interested in...
Study Finds Heart Device Trials Male-Dominated; FDA Promises Guidance
Women remain underrepresented in pivotal studies of cardiac devices submitted to FDA, and there is a lack of analysis distinguishing between trial outcomes in men and women, researchers conclude in a study published online March 1.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.